delpixel-shutterstock-com-brexit-
Delpixel / Shutterstock.com
20 October 2016EuropePaul England and Matthew Royle

Brexit: a fresh start for SPCs?

Under Regulation (EC) No. 469/2009, the exclusivity term of a pharmaceutical product protected by a patent can be extended by up to five years after that patent expires. This depends on the delay in obtaining a marketing authorisation (MA) for the pharmaceutical product and the subsequent impact that delay has on the period of exclusivity that the product enjoys on the market. This is achieved by the granting of a supplementary protection certificate (SPC) by the national offices of the EU member states in which the European patent has been on the register.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
10 July 2020   An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Big Pharma
11 July 2018   The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

More on this story

Big Pharma
10 July 2020   An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Big Pharma
11 July 2018   The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

More on this story

Big Pharma
10 July 2020   An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Big Pharma
11 July 2018   The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.